Skip to main content

Table 1 Model parameters

From: Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease

Parametersa

Values

Range

Distribution

Sources

General Mortality

0.0119

±25%

Log Normal

China Health and Family Planning Statistical Yearbook 2013 [18]

Relative risk of CKD Mortality

1.63

1.5–1.77

Log Normal

Chronic Kidney Disease Prognosis Consortium 2010 [30]

Relative risk reduction of CKD mortality after treatment

0.24

0.08–0.37

Log Normal

Heart Outcomes Prevention Evaluation (HOPE) Study Investigators 2000 [22]

Cost

 DAY-1

24.0

±25%

Gamma

Market price [21]

 Random

24.0

   

 DAY-1+ Random

48.0

   

 DAY-1+ Random + DAY-2

72.0

   

 RAS inhibitors

2867.2

   

 CKD annual cost

34205.0

 

Gamma

Wu et al.2014 [20]

Quality-Adjusted of Life Years

 CKD

0.899

±0.145

Beta

Wu et al.2014 [20]

  1. aValidity parameters of alternative strategies including true/false positive/negative rate were extracted from Table 3